ARTELO BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.35 USD | -2.17% |
|
+0.75% | -3.57% |
Presenter SpeechZunaid Suleman (Analysts)Welcome to the show. I'm looking forward to the conve...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid (CB) agonist that targets both the CB1 and CB2 receptors. This synthetic small molecule program is a G protein-coupled receptor (GPCR) designated ART27.13. ART27.13 is a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.35
USD
Average target price
16.67
USD
Spread / Average Target
+1,134.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.57% | 4.36M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- ARTL Stock
- News Artelo Biosciences, Inc.
- Transcript : Artelo Biosciences, Inc. - Special Call
